Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.
Original languageUnknown
Pages (from-to)513-27
JournalRevista Portuguesa de Cardiologia
Volume27
Issue number4
Publication statusPublished - 1 Jan 2008

Cite this

@article{936e607eb2d04aeab19e26291e5445d6,
title = "Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.",
abstract = "Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.",
author = "Sousa, {Maria Catarina Carapinha Salvado} and Clara, {Jo{\~a}o Pedro Pereira Gorj{\~a}o}",
year = "2008",
month = "1",
day = "1",
language = "Unknown",
volume = "27",
pages = "513--27",
journal = "Revista Portuguesa de Cardiologia",
issn = "0870-2551",
publisher = "Sociedade Portuguesa de Cardiologia",
number = "4",

}

TY - JOUR

T1 - Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.

AU - Sousa, Maria Catarina Carapinha Salvado

AU - Clara, João Pedro Pereira Gorjão

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.

AB - Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.

M3 - Article

VL - 27

SP - 513

EP - 527

JO - Revista Portuguesa de Cardiologia

JF - Revista Portuguesa de Cardiologia

SN - 0870-2551

IS - 4

ER -